Amino acid supplement
Beta-Alanine
Beta-Alanine after one dose: 50% at ~0.4 h, 25% at 0.8 h, 12.5% at 1.2 h.
Drawn from the half-life in the app's model, ~0.4 h. The model's figures
- Compound
- Beta-Alanine
- Symbol
- BA
- Family
- Supplements
- Parts
- 13
- References
- 9
- Checked
- Last reviewed . Sources are listed below.
Overview
Sources in this part
Beta-alanine is an amino acid supplement that the app files under supplements. Trexler and colleagues (position stand of the International Society of Sports Nutrition, Journal of the International Society of Sports Nutrition, 2015) describe carnosine as a dipeptide formed from L-histidine and beta-alanine and stored mainly in skeletal muscle.3 Hill and colleagues (University of Chichester, Amino Acids, 2007) write that "Muscle carnosine synthesis is limited by the availability of beta-alanine".2 The app's note calls it a carnosine precursor whose effect is not a plasma effect, because beta-alanine accumulates in muscle as carnosine over weeks. The human work described below is mostly in healthy adults and mostly measures muscle carnosine, exercise capacity and side effects; in a systematic review of 101 human studies, "The majority of studies were conducted on healthy young adults".5 The app grades the evidence for beta-alanine as strong; that grade is the app's own and is not a conclusion of the sources. No label for beta-alanine was identified in DailyMed.
How it works
Sources in this part
Trexler and colleagues state that carnosine "has been shown to be more effective at sequestering protons than either bicarbonate (pKa 6.3) or inorganic phosphate (pKa 7.2)" over the physiological pH range.3 They also report that early estimates from animals put carnosine at as much as 40 % of muscle buffering capacity, while "more recent research in humans has indicated the contribution may be as low as 7 %", and that "More evidence documenting the contribution of carnosine in muscle buffering is needed to further identify its role in exercise performance".3 The position stand says carnosinase, the enzyme that breaks carnosine down, "is present in serum and various tissues in humans, but is absent in skeletal muscle", and that "oral carnosine supplementation is an inefficient method of augmenting muscle carnosine levels in humans".3 Rezende and colleagues (University of São Paulo group, Frontiers in Physiology, 2020) analysed individual data from 99 participants in their own laboratory's studies and report that "effectually all participants respond to BA supplementation (99.3% response [95%CrI: 96.2-100])".4 The app's note says loading reaches saturation at about 28 days, but Rezende and colleagues conclude that "commonly used BA supplementation protocols may not come close to saturating muscle carnosine content".4 Beta-alanine shares a transporter with taurine: "Beta-alanine and taurine share the same transporter (Tau-T) into skeletal muscle".3 Dolan and colleagues (Advances in Nutrition, 2019) report that the tingling sensation is "most likely induced on binding of β-alanine to the peripheral neuronal receptor MrgprD".5
Half-life and pharmacokinetics
Values from the Milligram app's model.
- Half-life
- ~0.4 h
- Bioavailability
- 99%
- Typical dose
- 3.2–6.4 g/day
- Route
- Oral
- Time to peak
- ~0.5 h
Sources in this part
The second column holds the app's own figures, shown beside what the sources report.
| Parameter | App's figure | Reported in the sources |
|---|---|---|
| Half-life | ~0.4 h (the app's note says ~25 min) | 63.5 ± 8.7 min for a powder blend and 68.9 ± 9.8 min for a sustained-release tablet, after 8 g in a crossover trial of 12 randomised adults, 11 of whom completed it1 |
| Time to peak | ~0.5 h | 0.5 h for 1.6 g as a solution and 1.0 h for 1.6 g as a slow-release tablet in 11 adults6; Tmax 90 ± 13 min for the powder blend and 82 ± 14 min for the sustained-release tablet after 8 g in the 2021 crossover trial (p = 0.2767)1 |
| Bioavailability | 99% | Retention of 98.9% for the slow-release tablet against 96.3% for the solution after 1.6 g6; a 2.1-fold higher bioavailability for a controlled-release powder blend relative to a sustained-release tablet, which is a relative figure and not an absolute one1 |
| Time to return to baseline | ~2 h (the app's duration figure) | Plasma concentrations "regained baseline at 2 h" after single doses of 10, 20 and 40 mg/kg body weight7 |
| Peak plasma level by dose | Not given | 47 ± 13, 374 ± 68 and 833 ± 43 microM at 10, 20 and 40 mg/kg body weight, and 428 ± 66 microM when 40 mg/kg was given as histidine dipeptides in chicken broth7 |
The 63.5 to 68.9 minute half-lives come from one trial of single 8 g doses, and the powder blend in that trial also contained L-histidine 300 mg and carnosine 100 mg, so the figure is not for plain beta-alanine at the app's typical doses.1 The app's half-life of about 0.4 hours (24 minutes) is shorter than both figures, and the app's note says the effect depends on muscle carnosine and not on plasma levels. The position stand adds that non-responders and responders differ in how long muscle carnosine takes to return to baseline after supplementation stops, "requiring 6 to 15 weeks to return to normal".3
Human studies
| Study and year | Design | People | Dose and length | Main result |
|---|---|---|---|---|
| Harris and colleagues, Amino Acids 20067 | Clinical trial with single-dose plasma measurements and a 4-week supplementation phase; PubMed record gives no funding statement7 | Human volunteers; the number of people is not given in the PubMed record7 | Single doses of 10, 20 or 40 mg/kg; then 3.2 or 6.4 g/day, or isomolar L-carnosine, for 4 weeks7 | Muscle carnosine up an estimated 42.1% (3.2 g/day), 64.2% (6.4 g/day) and 65.8% (L-carnosine)7 |
| Hill and colleagues, Amino Acids 20072 | Placebo-controlled supplementation trial with muscle biopsies and a cycling capacity test; PubMed record gives no funding statement2 | 13 male subjects on beta-alanine, 12 matched subjects on placebo2 | 4 weeks (13 men) or 10 weeks (8 of them); the PubMed record does not give the daily dose2 | Muscle carnosine +58.8% at 4 weeks and +80.1% at 10 weeks, none in controls; total work done +13.0% at 4 weeks and a further +3.2% at 10 weeks, unchanged in controls2 |
| Décombaz and colleagues, Amino Acids 20126 | Single-blinded, randomised three-arm trial; first author at Nestlé Research Center, Lausanne6 | 11 healthy adults6 | 1.6 g as solution, 1.6 g as slow-release tablets, or placebo, once; 6 h of sampling6 | Peak plasma 82 against 248 μmol per litre for tablet against solution, with no difference in area under the curve; tablet symptoms could not be told apart from placebo6 |
| de Salazar and colleagues, Pharmaceutics 20211 | Randomised, single-blind crossover with a 1-week washout; supported by a university department, with the test product manufactured and provided by Martinez Nieto S.A.1 | 12 adults, 50% female; 11 completed1 | Single 8 g as a powder blend (with L-histidine 300 mg and carnosine 100 mg) or as 10 tablets (with zinc 20 mg)1 | Bioavailability 2.1-fold higher for the powder blend; half-life 63.5 and 68.9 min; paresthesia peak effect 1.7-fold higher on the visual analogue scale (p = 0.086) and on the categorical scale (p = 0.009)1 |
| Saunders and colleagues, British Journal of Sports Medicine 20178 | Systematic review and meta-analysis of double-blind, placebo-controlled studies; PubMed record gives no funding statement8 | 1461 participants in 40 studies, healthy participant populations8 | Chronic ingestion; crossover designs excluded8 | Overall effect size 0.18 (95% CI 0.08 to 0.28); within an exercise time frame of 0.5-10 min, exercise capacity 0.4998 (95% CI 0.246 to 0.753) against performance 0.1078 (95% CI -0.201 to 0.416)8 |
| Dolan and colleagues, Advances in Nutrition 20195 | Systematic risk assessment and meta-analysis of human and animal studies; grants from a Brazilian state research foundation5 | 2,268 humans in the analyses, 1,295 of them on active supplement5 | Longitudinal studies: median 6 g/day (range 1.6–12) for a median 28 days (range 7–168)5 | Paraesthesia odds ratio 8.9 (95% credible interval 2.2 to 32.6) against placebo; withdrawal odds ratio 0.72 (0.50 to 1.05); small rise in alanine aminotransferase5 |
| Rezende and colleagues, Frontiers in Physiology 20204 | Systematic review with dose-response meta-analysis plus an analysis of the authors' own individual data; grants from a Brazilian state research foundation4 | Published aggregate data, plus individual data from 99 participants4 | Dose-response model; protocols such as 4 weeks at 6.4 g/day4 | 99.3% responded (95% credible interval 96.2 to 100); common protocols "may not come close to saturating" muscle carnosine4 |
Deeper analysis: Harris and colleagues, 2006
Harris and colleagues (University College Chichester, Amino Acids, 2006) gave beta-alanine (CarnoSyn, NAI, USA) at 10, 20 and 40 mg/kg body weight, or as histidine dipeptides in chicken broth equivalent to 40 mg/kg.7 Plasma beta-alanine "peaked at 428 +/- SE 66, 47 +/- 13, 374 +/- 68 and 833 +/- 43 microM" for broth and the three pure doses, and "Concentrations regained baseline at 2 h".7 "Carnosine was not detected in plasma" after the broth, and plasma taurine rose after beta-alanine without "any increased loss via urine".7 After 4 weeks, 3.2 g/day, 6.4 g/day and isomolar L-carnosine gave "significant increases in muscle carnosine estimated at 42.1, 64.2 and 65.8%".7 The PubMed record lists the publication type "Research Support, Non-U.S. Gov't" and gives no funding statement, author ties to the supplement maker or limitations; the sample size is not given there either, so the full paper would be needed for those.7
Deeper analysis: Hill and colleagues, 2007
Hill and colleagues (University of Chichester, Amino Acids, 2007) supplemented 13 men with beta-alanine (CarnoSyn) for 4 weeks, 8 of them for 10 weeks, and compared them with 12 matched subjects on placebo.2 Muscle carnosine rose by "+58.8% and +80.1% after 4 and 10 wks", increased "equally in both type I and IIa fibres", and showed no increase in controls; taurine was unchanged by 10 weeks.2 Total work done in a cycle capacity test at 110% of maximum power rose by 13.0% at 4 weeks and a further 3.2% at 10 weeks, and the authors state that the "increase in TWD with supplementation followed the increase in muscle carnosine".2 Biopsies were taken from 6 of the 8 men supplemented for 10 weeks and from 5 of the 8 placebo subjects plus one additional subject, and the PubMed record gives no daily dose, funding statement, author ties or stated limitations.2
Deeper analysis: Décombaz and colleagues, 2012
Décombaz and colleagues (Nestlé Research Center, Lausanne, Amino Acids, 2012) set out "to compare plasma kinetics and symptoms following βA bolus administration in solution or in slow-release tablet form".6 Eleven healthy adults took 1.6 g as solution, 1.6 g as slow-release tablets or placebo after an overnight fast, in a single-blinded, randomised three-arm trial.6 Tablets gave a lower peak (82 against 248 μmol per litre), a later time to peak (1.0 against 0.5 h), no difference in area under the curve, less urinary loss (202 against 663 μmol) and retention of 98.9% against 96.3%.6 Maximum intensity scores were weaker with tablets than with the solution, and tablets and placebo "did not differ with respect to side-effects".6 The PubMed record does not state funding or limitations; the trial gave 11 people a single 1.6 g dose.6
Deeper analysis: de Salazar and colleagues, 2021
de Salazar and colleagues (Catholic University of Murcia, Pharmaceutics, 2021) compared a controlled-release powder blend with a sustained-release tablet at 8 g in a single-blind crossover trial with a 1-week washout.1 The powder blend gave Cmax and AUC 1.6- and 2.1-fold higher, "2.1-fold higher bioavailability", and similar half-lives of 63.5 and 68.9 minutes.1 Paresthesia peak effect rose 1.7-fold on the visual analogue scale (p = 0.086) and on the categorical scale (p = 0.009), and "No side effects were reported (except paresthesia)".1 The authors name limits including that "we did not measure β-alanine urinary excretion as our main objective was its bioavailability", that "in this study we only tested one dose level", and that "it remains unclear whether the 2.1-fold higher relative bioavailability would lead to its greater skeletal muscle fibers uptake and further synthesis to carnosine".1 Funding came from the university's Health Sciences Department, the authors "declare no conflict of interest", and the test product was manufactured and supplied by Martinez Nieto S.A.1
Deeper analysis: Dolan and colleagues, 2019
Dolan and colleagues (University of São Paulo and Robert Gordon University, Advances in Nutrition, 2019) searched four databases for human and animal studies of isolated oral beta-alanine, with searches completed in September 2018.5 Paraesthesia incidence in the high-quality studies (n = 22) was 18.6% on beta-alanine and 5.7% on placebo, and the authors state that "Participants in active treatment groups experienced similar dropout rates to those receiving the placebo treatment".5 The authors write that no evidence exists "to indicate that this is harmful, and thus it is not considered to represent an adverse event".5 In animals, taurine fell only at doses of "≥3% β-alanine in drinking water"; in humans, muscle taurine showed "no main effect" (effect size 0.156; 95% credible interval -0.38 to 0.72).5 The authors name limits of the evidence: "the assessment and reporting of side effects in human studies were suboptimal, thus limiting conclusions that can be drawn", and that the human taurine and histidine data "may have been insufficient to allow detection of small changes".5 On ties, the authors disclose that one author "has previously received a scholarship from Natural Alternatives International (NAI)" and that NAI "has also partially supported an original study conducted within our lab", with no input into the review; the work was funded by São Paulo research grants.5
Deeper analysis: Rezende and colleagues, 2020
Rezende and colleagues combined published aggregate data in a dose-response model with an original analysis of individual data from 99 participants in their own laboratory's studies.4 The authors caution that estimates at the high end of the curve are limited by "a paucity of data based on very high doses", which "limits precision regarding the point at which human skeletal muscle saturation occurs".4 Funding was from São Paulo and Brazilian research agencies; one author "has previously received a scholarship from Natural Alternatives International (NAI)", which "has also partially supported an original study conducted within our laboratory" and had no input into the review.4
Deeper analysis: Saunders and colleagues, 2017 and the position stand
Saunders and colleagues (University of São Paulo and Nottingham Trent University, British Journal of Sports Medicine, 2017) pooled 40 double-blind, placebo-controlled studies and report an overall effect size of 0.18 (95% CI 0.08 to 0.28).8 The exercise-performance subgroup interval (-0.201 to 0.416) includes zero.8 The PubMed record for this review does not state funding or author ties to a supplement maker.8 The position stand reports that "Daily supplementation with 4 to 6 g of beta-alanine for at least 2 to 4 weeks has been shown to improve exercise performance, with more pronounced effects in open end-point tasks/time trials lasting 1 to 4 min in duration".3 It lists author ties: one author "has been funded by Natural Alternatives Inc., in support of research with beta-alanine", and another "has received research support from companies to study beta-alanine and has co-formulated products containing beta-alanine", one is "Director of Research for the dietary supplement company, Nutrabolt", and one "currently serves as a scientific consultant for Nutrabolt".3
Doses reported in studies and on labels
| Source | Dose | Length and form | Measured |
|---|---|---|---|
| Harris and colleagues 20067 | 3.2 and 6.4 g/day as multiple doses of 400 or 800 mg | 4 weeks of supplementation | Muscle carnosine up an estimated 42.1% and 64.2% |
| Harris and colleagues 2006, single doses7 | 10, 20 and 40 mg/kg body weight | Single oral doses | Plasma peaks of 47, 374 and 833 microM |
| Décombaz and colleagues 20126 | 1.6 g | Single dose as solution or slow-release tablets, 11 adults | Peak plasma 248 against 82 μmol per litre |
| de Salazar and colleagues 20211 | 8 g | Single dose as powder blend with L-histidine 300 mg and carnosine 100 mg, or 10 tablets with zinc 20 mg; crossover, 12 adults | Half-life 63.5 and 68.9 min |
| Dolan and colleagues 2019, longitudinal studies5 | Median 6 g/day (range 1.6–12) | Median 28 days (range 7–168) across 94 longitudinal studies | Side effects |
| ISSN position stand 20153 | 4 to 6 g daily in divided doses of 2 g or less | For a minimum of two weeks, with greater effect after 4 weeks | Muscle carnosine; the authors say optimal loading and maintenance doses cannot yet be given |
| Product labels | No label identified | Search of DailyMed for "beta-alanine" returned 0 labels | Not applicable |
The app lists a typical dose of 3.2 to 6.4 g/day, which matches the two daily doses in the Harris trial; the longitudinal studies reviewed by Dolan and colleagues used a median of 6 g/d (range 1.6 to 12), and the authors write that "Intakes up to 6.4 g/d were commonly used in the studies included within this review".7,5
Side effects reported
Sources in this part
Dolan and colleagues report paraesthesia as "the only reported side effect", with an odds ratio of 8.9 (95% credible interval 2.2 to 32.6) against placebo, and incidence of 18.6% against 5.7% in the high-quality studies.5 In a narrative synthesis of 8 acute studies the review reports that "The extent and time to peak blood β-alanine concentration emerged as the primary determinant of the occurrence and intensity of paraesthesia", while for the longitudinal studies it states that heterogeneity "precluded statistical identification of factors that moderated paraesthesia".5 The position stand says the tingling is "typically experienced in the face, neck, and back of hands", has "generally been reported to disappear within 60 to 90 min following supplementation" with non-sustained-release products, and is "typically dose-dependent".3 In one longitudinal study of 6 g/day for 28 days cited by Dolan and colleagues, the rapid-release group "reported a more frequent paraesthesia occurrence" than the sustained-release group, and the sustained-release group reported paraesthesia at a rate similar to placebo.5 In the acute trial by Décombaz and colleagues, maximum intensity scores were weaker with tablets than with the 1.6 g solution, and tablets and placebo "did not differ with respect to side-effects".6 Dolan and colleagues report no difference in withdrawal rates (odds ratio 0.72; 95% credible interval 0.50 to 1.05) and write that no evidence indicates the tingling is harmful; the app's note calls it harmless.5
Bloodwork and markers
Sources in this part
The app lists no markers to monitor for beta-alanine. Dolan and colleagues identified seven studies of circulating health-related markers, "comprising 220 individuals, with 87 of these taking the active β-alanine supplement", and "No individual study reported a significant change to any of the measured biomarkers".5 Pooled across studies, supplementation was associated with a small increase in alanine aminotransferase (effect size 0.274; 95% credible interval 0.04 to 0.527), "although mean data remained well within clinical reference ranges".5 The same review also reports "trends toward significantly increased alkaline phosphatase (ALP; ES: 0.434; 95% CrI: −0.067, 0.811) and sodium (ES: 0.497; 95% CrI: −0.033, 1.063)".5 The review also reports that a 12-lead ECG in one trial "reported no change to cardiac function after a 4-wk β-alanine supplementation intervention".5
Regulatory and anti-doping status
Sources in this part
A search of the text of the WADA 2026 Prohibited List, which states that it is valid from 1 January 2026, for "alanine" returned no match.9 The list's S0 class covers "Any pharmacological substance which is not addressed by any of the subsequent sections", and the text search above did not assess whether that class applies to a dietary amino acid.9 No DailyMed label was identified for the query "beta-alanine".
What is not known
Sources in this part
The position stand states that "there is no safety data on the long-term use of beta-alanine" beyond one year.3 The point at which human muscle carnosine saturates is not established; Rezende and colleagues note a "paucity of data based on very high doses".4 The position stand states that "the maximal concentration or retention of carnosine in human muscle is not well known".3 It is unclear whether higher plasma availability from a new formulation raises muscle carnosine, because de Salazar and colleagues did not measure muscle.1 The plasma half-life reported here comes from a single 8 g trial, and the trials cited give retention and relative bioavailability rather than an absolute oral bioavailability, so the sources give a different half-life from the app's 0.4 h and do not confirm the app's 99%.1
Frequently asked questions
What is the half-life of beta-alanine?
A 2021 crossover trial of 8 g reported plasma half-lives of 63.5 ± 8.7 min and 68.9 ± 9.8 min for two formulations, and the app lists about 0.4 hours.1 The app's note says the plasma half-life is not what matters, because beta-alanine accumulates in muscle as carnosine over weeks.
How long does beta-alanine take to peak in blood?
After 1.6 g, Décombaz and colleagues report a time to peak of 0.5 h for a solution and 1.0 h for slow-release tablets, and the app lists about 0.5 hours.6 After 8 g, de Salazar and colleagues report Tmax of 90 ± 13 minutes for the powder blend and 82 ± 14 minutes for the sustained-release tablet (p = 0.2767).1
What is the bioavailability of beta-alanine?
The app lists 99%; Décombaz and colleagues report retention of 98.9% for slow-release tablets and 96.3% for solution after 1.6 g, which is retention and not an absolute oral bioavailability, and de Salazar and colleagues report a 2.1-fold higher bioavailability for a controlled-release powder blend relative to a sustained-release tablet after 8 g.6,1
Does beta-alanine raise muscle carnosine?
Why does beta-alanine cause tingling?
Dolan and colleagues write that the sensation is "most likely induced on binding of β-alanine to the peripheral neuronal receptor MrgprD", and that paraesthesia "closely matches the extent and time to peak blood β-alanine concentrations".5
Does beta-alanine improve exercise performance?
Is beta-alanine banned by WADA?
What is the only side effect of beta-alanine reported in trials?
Dolan and colleagues report paraesthesia as the only side effect reported in the human trials they reviewed, with an odds ratio of 8.9 against placebo, and write that "the assessment and reporting of side effects in human studies were suboptimal, thus limiting conclusions that can be drawn".5
How long do raised muscle carnosine levels last after stopping beta-alanine?
The position stand says washout time "may vary between non-responders and responders, requiring 6 to 15 weeks to return to normal".3
Guides, tools and comparisons
References
- de Salazar L, et al. Increased Bioavailability of β-Alanine by a Novel Controlled-Release Powder Blend Compared to a Slow-Release Tablet. Pharmaceutics 2021. PMC8467909
- Hill CA, et al. Influence of beta-alanine supplementation on skeletal muscle carnosine concentrations and high intensity cycling capacity. Amino Acids 2007. PMID 16868650
- Trexler ET, et al. International society of sports nutrition position stand: Beta-Alanine. J Int Soc Sports Nutr 2015. PMC4501114
- Rezende NS, et al. The Muscle Carnosine Response to Beta-Alanine Supplementation: A Systematic Review With Bayesian Individual and Aggregate Data E-Max Model and Meta-Analysis. Front Physiol 2020. PMC7456894
- Dolan E, et al. A Systematic Risk Assessment and Meta-Analysis on the Use of Oral β-Alanine Supplementation. Adv Nutr 2019. PMC6520041
- Décombaz J, et al. Effect of slow-release β-alanine tablets on absorption kinetics and paresthesia. Amino Acids 2012. PMID 22139410
- Harris RC, et al. The absorption of orally supplied beta-alanine and its effect on muscle carnosine synthesis in human vastus lateralis. Amino Acids 2006. PMID 16554972
- Saunders B, et al. β-alanine supplementation to improve exercise capacity and performance: a systematic review and meta-analysis. Br J Sports Med 2017. PMID 27797728
- World Anti-Doping Agency. World Anti-Doping Code International Standard: Prohibited List 2026. WADA list